Genzyme Biosurgery may turn you into the Six Million Dollar Man, but it can't do anything about your Six Million Dollar Medical Bill. The company develops and sells biological materials for orthopedic and general surgical procedures. Top sellers include Synvisc and Synvisc-One, which are injectable biomaterials for the treatment of pain from osteoarthritis of the knee and other joints, and Seprafilm, which prevents tissue adhesions after surgery. Other products include biomaterials that assist in hernia repair (Sepramesh), repair of damaged knee cartilage (Carticel), and severe burn treatment (Epicel). Genzyme Biosurgery is a unit of biotech drug developer Genzyme, which was acquired by Sanofi in 2011.